The BioMed X Institute
19.12.2023 10:03:15 CET | ACCESS Newswire | Press release
German research institute BioMed X and Ono Pharmaceutical, a Japanese pharmaceutical company, started a new joint research project on cancer immunotherapies.
HEIDELBERG, GERMANY / ACCESSWIRE / December 19, 2023 / BioMed X announced today a new joint research project with Ono Pharmaceutical Co., Ltd, marking the start of the collaboration between the German biomedical research institute and one of the largest pharmaceutical companies in Japan. The project entitled "New Strategies to Engage Neutrophils in Solid Tumors" will be hosted by the BioMed X Institute in Heidelberg, Germany. The goal of this research project is to design next-generation immunotherapies by leveraging the antitumor effects of neutrophils.
Developing immunotherapies that target T cells has proved highly effective, and it is still a rapidly evolving research area. However, many patients remain resistant to these therapies, necessitating the development of novel immunological strategies. The presence of neutrophils in solid tumors has been well-documented, albeit their role in the tumor microenvironment seems to be paradoxical according to the data accumulated thus far. By uncovering novel neutrophil biology, this project aims to leverage their functions to design novel immunotherapies.
The new research team will join nine other research groups at the BioMed X Institute in Heidelberg, Germany. Researchers who are interested in becoming part of this new research group are invited to respond to this international call for application by submitting a project proposal via the BioMed X Career Space at https://career.bio.mx/call/2023-BMX-C03 before February 18, 2024.
Christian Tidona, Founder and Managing Director of the BioMed X Institute: "Oncology and immunology, including tumor immunology, are key areas of expertise at BioMed X. We are proud and honored that Ono has chosen our institute to develop new strategies for engaging neutrophils in cancer therapy".
Toichi Takino, Senior Executive Officer/Executive Director, Discovery & Research at Ono Pharmaceutical: "We are very pleased to form a partnership with BioMed X in our mission dedicated to overcoming cancer. This innovative research collaboration will engage us with highly talented scientists around the world who possess unique ideas for immunotherapy utilizing neutrophils. We believe that the research team established through this collaboration will lead to the discovery of the next generation of immunotherapy with us".
About BioMed X
BioMed X is an independent research institute with sites in Heidelberg, Germany, New Haven, Connecticut, XSeed Labs in Ridgefield, Connecticut, and a worldwide network of partner locations. Together with our partners, we identify big biomedical research challenges and provide creative solutions by combining global crowdsourcing with local incubation of the world's brightest early-career research talents. Each of the highly diverse research teams at BioMed X has access to state-of-the-art research infrastructure and is continuously guided by experienced mentors from academia and industry. At BioMed X, we combine the best of two worlds - academia and industry - and enable breakthrough innovation by making biomedical research more efficient, more agile, and more fun.
About Ono
Ono Pharmaceutical Co., Ltd., headquartered in Osaka, Japan, is an R&D-oriented pharmaceutical company committed to creating innovative medicines in specific areas. Ono focuses its research on oncology, immunology, neurology and specialty research with high medical needs as priority areas for discovery and development of innovative medicines. For further information, please visit the company's website at https://www.ono-pharma.com/en.
Contact Information
Flavia-Bianca Cristian
Recruiting & Communications Manager
fbc@bio.mx
+49 6221 426 11 706
View the original press release on newswire.com.
SOURCE: BioMed X Institute
To view this piece of content from stats.newswire.com, please give your consent at the top of this page. To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
GoodData is Now GoodData.AI, Reflecting Its AI-First Direction30.4.2026 11:00:00 CEST | Press release
The brand update marks the company's continued shift toward intelligence-driven analytics. SAN FRANCISCO, CA / ACCESS Newswire / April 30, 2026 / GoodData, the AI-native decision intelligence platform, today announced it is rebranding as GoodData.AI. The rebrand reflects a strategic direction GoodData has been building toward for several years. The platform has been developed around a core conviction: that governed, AI-native analytics is the foundation every serious enterprise needs. The semantic layer, context management, open architecture, composability, agentic frameworks, and analytics-as-code introduced over that period were each a step toward that foundation. "GoodData.AI is the name that reflects both where we've been and where the market is going," said Roman Stanek, CEO and Founder of GoodData.AI. "Enterprises need analytics that AI can operate, govern, and trust at scale. That's what we're built for, and we're moving faster than ever to get customers there." That pace is vis
Karbon-X Introduces Corporate Emissions Calculator as Pressure to Quantify Carbon Exposure Accelerates29.4.2026 15:10:00 CEST | Press release
Digital tool enables companies to rapidly assess emissions and take immediate action while preparing for compliance and carbon market participation. CALGARY, AB / ACCESS Newswire / April 29, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions provider operating across compliance and voluntary carbon markets, today highlighted its Corporate Emissions Calculator, a digital tool designed to help organizations quickly quantify emissions across key operational areas and move from measurement to action. As regulatory frameworks evolve and expectations around emissions disclosure increase, organizations across sectors including energy, manufacturing, aviation, and logistics are facing accelerating pressure to understand and manage their carbon exposure. Many existing solutions remain complex, time-intensive, and reliant on external consultants, creating delays at a time when companies are being pushed to act faster and with greater preci
Global Nurse Migration Patterns Shift as Europe, Southeast Asia Absorb Growing Share of International Nurses28.4.2026 16:00:00 CEST | Press release
TruMerit 2025 Nurse Migration Report reveals workforce inequities widening across regions. PHILADELPHIA, PA / ACCESS Newswire / April 28, 2026 / TruMerit™ (formerly CGFNS International) today released its 2025 Nurse Migration Report, revealing significant shifts in global nurse migration patterns and widening inequities in nursing workforce distribution across regions with vastly different healthcare needs. The report, which analyzes World Health Organization data and TruMerit's proprietary VisaScreen® application records, shows that international nurse migration flows are increasingly concentrated in regions with stronger healthcare infrastructure, while areas facing severe nursing shortages continue to lose ground in their ability to employ internationally educated nurses. Europe and Southeast Asia see sharp increases in international nurse employment. According to TruMerit's analysis of WHO nursing workforce data, Europe now employs internationally educated nurses at a rate represen
Tenstorrent Enables AI At Scale with Industry-Leading Performance Deployed on Novel Networked AI Architecture28.4.2026 15:00:00 CEST | Press release
Tenstorrent GalaxyTM Blackhole delivers general-purpose AI with native scale-out for winning performance in AI video generation and LLMs - prefill and decode. SANTA CLARA, CA / ACCESS Newswire / April 28, 2026 / Tenstorrent, the AI compute company led by CEO, Jim Keller, announces today general availability of Tenstorrent Galaxy Blackhole deployed at scale, delivering industry-leading general-purpose AI performance. Other solutions require bolting together separate accelerators across fragmented infrastructure. Tenstorrent's Networked AI delivers them natively - compute, memory, and networking unified into a single system optimized for real-world AI workloads. Leading Industry Performance, Affordable Prices General-purpose means leading performance on every workload defining modern AI, not specializing in one. Tenstorrent Galaxy tops video generation, large-context LLM inference in both prefill and decode, and the full range of model architectures shipping today. See it for yourself on
Kontent.ai Appoints Mark Greenaway as CEO to Drive the Next Phase of AI in Enterprise Content27.4.2026 08:00:00 CEST | Press release
BRNO, CZ / ACCESS Newswire / April 27, 2026 / Kontent.ai has appointed Mark Greenaway as Chief Executive Officer, as the company looks to scale its Agentic CMS and transform content operations for customers. Greenaway brings a track record of scaling businesses and leading high performing global teams with a focus on enterprise environments where content is both a marketing asset and a critical driver of growth, compliance, and customer experience. With this appointment, Kontent.ai founder Petr Palas returns to his position on the board at Kontent.ai and will continue to support the business he launched in 2022 as a successful spin out of Kentico. Kontent.ai recently launched their next generation of "Agentic CMS" with the launch of Expert Agents. These Agents are embedded directly into workflows to continuously handle operational tasks such as governance, search and generation engine (LLM) optimization, translation, and lifecycle management, work that typically requires significant ma
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom